Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 377.50M P/E - EPS this Y 14.90% Ern Qtrly Grth -
Income -52.32M Forward P/E -8.47 EPS next Y 20.60% 50D Avg Chg -5.00%
Sales 79.39M PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 2.58 EPS next 5Y - 52W High Chg -49.00%
Recommedations 2.60 Quick Ratio 10.39 Shares Outstanding 50.31M 52W Low Chg 46.00%
Insider Own 20.16% ROA -19.36% Shares Float 29.89M Beta 2.72
Inst Own 50.87% ROE -44.01% Shares Shorted/Prior 1.04M/1.13M Price 7.79
Gross Margin 85.80% Profit Margin -65.90% Avg. Volume 115,158 Target Price 7.38
Oper. Margin -59.20% Earnings Date Nov 5 Volume 103,416 Change -3.41%
About Sight Sciences, Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences, Inc. News
03:05 PM Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
09/30/24 Institutional investors own a significant stake of 34% in Sight Sciences, Inc. (NASDAQ:SGHT)
08/21/24 AmEx downgraded, Texas Instruments upgraded: Wall Street's top analyst calls
08/20/24 Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
08/02/24 Q2 2024 Sight Sciences Inc Earnings Call
08/01/24 Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
08/01/24 Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance
07/25/24 Integer (ITGR) Q2 Earnings Surpass Estimates
07/18/24 Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
07:01 AM One Sight Sciences Insider Raised Stake By 34% In Previous Year
06/10/24 Sight Sciences Announces the Release of its First Sustainability Report
05/28/24 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
05/28/24 Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
05/07/24 Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
05/06/24 Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript
05/04/24 Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/03/24 Q1 2024 Sight Sciences Inc Earnings Call
05/02/24 Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
05/02/24 Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
04/30/24 Sight Sciences awarded $34m in Alcon patent infringement case
SGHT Chatroom

User Image insiderbuyingselling Posted - 1 week ago

$SGHT new insider selling: 3167 shares. http://insiderbuyingselling.com/?t=SGHT

User Image insiderbuyingselling Posted - 1 week ago

$SGHT new insider selling: 12727 shares. http://insiderbuyingselling.com/?t=SGHT

User Image G101SPM Posted - 1 week ago

$SGHT $5.92 bid. DAC $6.08 (8.21.24). EXIT $11.50 RETAIN POSITION. BRIEF: On October 3, 2024, four Medicare Administrative Contractors (MACs, each published final local coverage determinations and related final local coverage articles regarding Micro-Invasive Glaucoma Surgery ('MIGS'). ^^ ^^^ Coverage for canaloplasty in combination with trabeculotomy ab interno procedures and goniotomy procedures will continue in the states covered by these MACs; effective November 17, 2024.

User Image G101SPM Posted - 09/27/24

$SGHT $6.57 last bid. DAC $6.08 (8.21.24. EXIT $11.5-. BRIEF: On 9.26.24 26, Noridian Healthcare Solutions, the Medicare Administrative Contractor ("MAC") for sixteen (16) states and U.S. territories, published a final local coverage determination and related final local coverage article (collectively, the "Final LCD") regarding Micro-Invasive Glaucoma Surgery ("MIGS"). The Final LCD, which is substantially similar to the proposed LCD published by Noridian in May 2024, confirms Medicare coverage for phacoemulsification / intraocular lens placement procedures performed with a single MIGS procedure. The Company plans to continue to engage with each MAC, the Centers for Medicare and Medicaid Services, and the clinical societies in continued support of procedures performed with OMNI and SION.

User Image insidemoney Posted - 08/27/24

$SGHT Sight Sciences Inc. 14-Day RSI: 60.2 % from 52-Week Low: +577.9% % from 52-Week High: -16.6% Open Interest: 932 % Change: +1% Put/Call Ratio: 0.24 % Change: -1.5%

User Image G101SPM Posted - 08/21/24

$SGHT $6.12 bid. Hold long position UPDATE FROM THE OTHER SIDE: Sight Sciences: Underappreciated reimbursement visibility, returning to growth, shares still cheap; initiating with Buy rating and $10 PT -- Lake Street . Analyst Frank Takkinen commented, "We believe investors are underappreciating Sight's ability to reaccelerate growth from -4% Y/Y in 1H24 toward historical rates (2020-2023 CAGR: 43%). We remain conservative, but, assuming policies are finalized in their current form, we think 13% consensus growth in 2025 will be too low. Despite shares rebounding >4x from 2023 lows, we think there is still a disconnect vs. comps and expect policy finalization, execution, and upside to numbers to close the remaining valuation gap. Shares trade at 2.4x '25 EV/Rev vs. pure-play ophthalmology at 6.6x. The balance sheet is solid with $118M of cash at Q2'24 end (Q2'24 burn: $9M). We think proposals are relatively derisked near-term catalysts."

User Image G101SPM Posted - 08/21/24

$SGHT $6.08 ask. BUY/NEW LONG POSITION carries SPM 87.74 tag to EXUT $11.50 in midterm.

User Image lawson Posted - 2 months ago

$SGHT IPO @ $24 if I recall correctly. Tanked all the way to a ~buck and now trades 75% below the IPO price. CEO Paul Badawi, perhaps you could resign and let a better performing CEO take over?

User Image lawson Posted - 2 months ago

$SGHT CEO Paul Badawi has IMO seemingly shit the bed. Flat performance and huge cash burn. The PPS should tell him what wall street thinks of his performance.

User Image Sc_McDuck Posted - 2 months ago

$SGHT Poop.

User Image Stock_Titan Posted - 2 months ago

$SGHT Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance https://www.stocktitan.net/news/SGHT/sight-sciences-reports-second-quarter-2024-financial-results-and-o3fnnty9w41m.html

User Image NVDAMillionaire Posted - 2 months ago

$SGHT Sight Sciences, Inc. (NASDAQ:SGHT): Transforming Ophthalmic Care with Innovative Surgical and Dry Eye Solutions http://beyondspx.com/2024/07/31/sight-sciences-inc-nasdaqsght-transforming-ophthalmic-care-with-innovative-surgical-and-dry-eye-solutions/

User Image lawson Posted - 07/31/24

$SGHT Earning to be announced tomorrow. Hoping for more good news.

User Image Doozio Posted - 07/25/24

Thursday 🐑 low unless yo $blnd. A 🧠⏰ FRYday is in $sght YO $hear

User Image Doozio Posted - 07/23/24

Chop chop huckleberries n don’t $BLNK or yo maybe $blnd with out $sght during 🧠⏰♾️

User Image Doozio Posted - 07/23/24

Bahhht whut happens wen da 🐑 isn’t $blnd no moar n has $sght goin $yrd in 🧠⏰♾️?

User Image StockBoyAri Posted - 07/23/24

$SGHT this moves quick it looks like. I like $9+ here just my opinion.

User Image Stock_Titan Posted - 07/18/24

$SGHT Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 https://www.stocktitan.net/news/SGHT/sight-sciences-to-report-second-quarter-financial-results-on-august-abjk2rd70t3s.html

User Image KCclean Posted - 07/16/24

$SGHT yes

User Image Doozio Posted - 07/16/24

Even da $blnd bums are starting TTWO get their $sght in 🧠⏰♾️

User Image StockBoyAri Posted - 07/15/24

$SGHT $9+ here

User Image lawson Posted - 3 months ago

$SGHT great week

User Image KCclean Posted - 3 months ago

$SGHT yes

User Image Thestocktraderhubzee Posted - 3 months ago

WATCHLIST JUL 11 2024. $TAP Citigroup Maintains Sell on Molson Coors Beverage, Lowers Price Target to $47 $KRUS Citigroup Maintains Neutral on Kura Sushi USA, Lowers Price Target to $68 $SGHT Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6.5 $MDT Citigroup Maintains Neutral on Medtronic, Lowers Price Target to $85 $IART Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $30

User Image _www_larval_com_ Posted - 3 months ago

$SGHT just dropped -5% lower to -4% (~569Kv) a few minutes ago, 07/19 options, follow for more volatility.

User Image KCclean Posted - 3 months ago

$SGHT next leg?

User Image insiderbuyingselling Posted - 3 months ago

$SGHT new insider selling: 3525 shares. http://insiderbuyingselling.com/?t=SGHT

User Image insiderbuyingselling Posted - 3 months ago

$SGHT new insider selling: 3128 shares. http://insiderbuyingselling.com/?t=SGHT

User Image tonyctl Posted - 06/18/24

@cubie @simon58 @jenbunn @jargv @ribbey @kindness123 @TraderRapp @tigerknee @lukenight @pinkyj total volume about 1000 on $sght puts which is not that significant but it’s so out of money, maybe some got scared after $AVTE and bought puts for protection who knows 🤷‍♂️

User Image cubie Posted - 06/18/24

@simon58 @jenbunn @jargv @ribbey @kindness123 @TraderRapp @tonyctl @tigerknee @lukenight @pinkyj $sght

Analyst Ratings
Lake Street Buy Aug 21, 24
Needham Hold Aug 2, 24
Morgan Stanley Equal-Weight Jul 15, 24
Citigroup Neutral Jul 10, 24
Piper Sandler Neutral May 3, 24
Needham Hold May 3, 24
Needham Hold Apr 10, 24
Stifel Buy Mar 8, 24
Morgan Stanley Equal-Weight Dec 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Badawi Paul President and CEO President and CEO Jan 17 Sell 5.164 15,917 82,195 5,319,539 01/19/24
Badawi David Chief Technology Off.. Chief Technology Officer Jan 17 Sell 5.164 3,414 17,630 1,642,157 01/19/24
D1 Capital Partners L.P. 10% Owner 10% Owner Dec 27 Sell 5.86 2,852,036 16,712,931 3,000,000 12/29/23
Encrantz Staffan Director Director Nov 29 Buy 3.48 144,000 501,120 1,012,150 12/01/23
Encrantz Staffan Director Director Nov 24 Buy 3.29 521,855 1,716,903 868,150 11/28/23
Badawi David Chief Technology Off.. Chief Technology Officer Nov 24 Option 0.11 150,000 16,500 1,631,196 11/28/23
Encrantz Staffan Director Director Nov 20 Buy 2.41 188,796 454,998 346,295 11/22/23
Encrantz Staffan Director Director Nov 16 Buy 2.09 127,003 265,436 157,499 11/20/23
Park Sam Boong Chief Operating Offi.. Chief Operating Officer Sep 14 Option 1.96 37,668 73,829 89,092 09/15/23
Park Sam Boong Chief Operating Offi.. Chief Operating Officer Feb 26 Option 1.96 20,332 39,851 44,664 01/05/23
Badawi David Chief Technology Off.. Chief Technology Officer Sep 21 Option 0.23 40,000 9,200 1,481,196 09/23/22
Selnick Jesse Chief Financial Offi.. Chief Financial Officer May 11 Option 0.49 150,000 73,500 399,225 05/23/22
Encrantz Staffan Director Director May 13 Buy 8.23 551,802 4,541,330 551,802 05/17/22
Encrantz Staffan Director Director Nov 29 Buy 20.68 525,000 10,857,000 4,022,118 12/01/21